Camrelizumab
Today, Camrelizumab is a highly relevant topic that generates interest and debate in various areas. With the passage of time, Camrelizumab has become increasingly important in today's society, and its influence is noticeable in different aspects of daily life. From the personal sphere to the work sphere, Camrelizumab has proven to be a topic that does not go unnoticed, arousing the interest of experts, academics and people in general. In this article, we will explore different aspects related to Camrelizumab, as well as its impact on today's society.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PD1 |
| Clinical data | |
| Other names | SHR-1210 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Camrelizumab (SHR-1210) (INN[1]) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.[2] PD-1 is programmed cell death protein 1.
The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2019, camrelizumab is undergoing Phase II/III trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
- ^ Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. (June 2019). "Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma". Journal of Clinical Oncology. 37 (17): 1479–1489. doi:10.1200/JCO.18.02151. PMID 31039052. S2CID 141482897.
{{cite journal}}: CS1 maint: overridden setting (link)
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |